StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Saturday. The firm set a “sell” rating on the stock.

VNRX has been the subject of several other research reports. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research report on Tuesday.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.57 on Friday. The stock has a fifty day moving average price of $0.68 and a 200 day moving average price of $0.67. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The company has a market cap of $52.36 million, a PE ratio of -1.57 and a beta of 1.17.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.